CN1198610C - 神经紊乱的治疗 - Google Patents

神经紊乱的治疗 Download PDF

Info

Publication number
CN1198610C
CN1198610C CNB008100292A CN00810029A CN1198610C CN 1198610 C CN1198610 C CN 1198610C CN B008100292 A CNB008100292 A CN B008100292A CN 00810029 A CN00810029 A CN 00810029A CN 1198610 C CN1198610 C CN 1198610C
Authority
CN
China
Prior art keywords
treatment
test
citalopram
medicine
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008100292A
Other languages
English (en)
Chinese (zh)
Other versions
CN1360501A (zh
Inventor
C·桑切兹
S·霍格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lingbei United Co ltd
H Lundbeck AS
Original Assignee
Lingbei United Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1198610(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lingbei United Co ltd filed Critical Lingbei United Co ltd
Publication of CN1360501A publication Critical patent/CN1360501A/zh
Application granted granted Critical
Publication of CN1198610C publication Critical patent/CN1198610C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB008100292A 1999-07-08 2000-07-07 神经紊乱的治疗 Expired - Lifetime CN1198610C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
DKPA199900991 1999-07-08

Publications (2)

Publication Number Publication Date
CN1360501A CN1360501A (zh) 2002-07-24
CN1198610C true CN1198610C (zh) 2005-04-27

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008100292A Expired - Lifetime CN1198610C (zh) 1999-07-08 2000-07-07 神经紊乱的治疗

Country Status (38)

Country Link
US (6) US7271194B2 (xx)
EP (4) EP1440690A3 (xx)
JP (1) JP4773011B2 (xx)
KR (1) KR100604176B1 (xx)
CN (1) CN1198610C (xx)
AR (1) AR021155A1 (xx)
AT (1) ATE339955T1 (xx)
AU (6) AU782514B2 (xx)
BG (4) BG110467A (xx)
BR (1) BR0011578A (xx)
CA (4) CA2687394A1 (xx)
CL (3) CL2008003938A1 (xx)
CO (1) CO5190674A1 (xx)
CY (1) CY1105806T1 (xx)
CZ (1) CZ200270A3 (xx)
DE (1) DE60030861T2 (xx)
DK (1) DK1200081T3 (xx)
EA (1) EA006555B1 (xx)
ES (1) ES2272298T3 (xx)
HK (1) HK1048069B (xx)
HR (1) HRP20010820A2 (xx)
HU (1) HUP0201791A3 (xx)
IL (5) IL146131A0 (xx)
IS (1) IS6137A (xx)
ME (2) ME00032B (xx)
MX (1) MXPA01011626A (xx)
MY (1) MY143278A (xx)
NO (4) NO329021B1 (xx)
PL (1) PL352030A1 (xx)
PT (1) PT1200081E (xx)
SI (1) SI1200081T1 (xx)
SK (1) SK82002A3 (xx)
TR (4) TR200200014T2 (xx)
TW (1) TWI232101B (xx)
UA (1) UA77645C2 (xx)
WO (1) WO2001003694A1 (xx)
YU (1) YU78701A (xx)
ZA (1) ZA200108856B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
PT1301502E (pt) * 2000-07-21 2005-09-30 Lundbeck & Co As H Compostos e sua utilizacao como inibidores do transporte de glicina
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
DK1414435T3 (da) 2001-07-31 2005-05-09 Lundbeck & Co As H Krystallinsk komposition indeholdende escitalopram
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
KR20050086933A (ko) * 2002-12-23 2005-08-30 하. 룬트벡 아크티에 셀스카브 브롬화수소산에스시탈로프람 및 이의 제조방법
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (xx) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
DK0612242T3 (da) 1991-11-15 2003-10-20 Sepracor Inc Anvendelse af ren S(+)-isomer af fluoxetin til fremstilling af et medikament mod migræne
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
EP0759299B1 (en) 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
CN1286687A (zh) * 1997-11-11 2001-03-07 H·隆德贝克有限公司 制备西酞普兰的方法
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
DE69904853T2 (de) * 1998-10-20 2003-09-04 Lundbeck As Valby H Verfahren zur herstellung von citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
NZ514671A (en) * 1999-04-14 2003-10-31 H Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU5565401A (en) 2000-04-24 2001-11-07 Aryx Therapeutics Materials and methods for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram

Also Published As

Publication number Publication date
MEP2508A (xx) 2010-02-10
JP4773011B2 (ja) 2011-09-14
AU2005202686A1 (en) 2005-07-14
EP1200081A1 (en) 2002-05-02
TWI232101B (en) 2005-05-11
IL170192A (en) 2010-04-29
TR200200014T2 (tr) 2002-05-21
CA2687394A1 (en) 2001-01-18
AU2008264182A1 (en) 2009-01-29
TR200402276T2 (tr) 2005-01-24
AR021155A1 (es) 2002-06-12
NO20020062D0 (no) 2002-01-07
EP1440690A3 (en) 2004-08-18
DE60030861T2 (de) 2007-05-03
IL146131A (en) 2007-02-11
AU5806100A (en) 2001-01-30
BG110466A (en) 2010-01-29
CL2008003941A1 (es) 2009-05-22
BG110468A (en) 2010-01-29
CN1360501A (zh) 2002-07-24
EA006555B1 (ru) 2006-02-24
CY1105806T1 (el) 2011-02-02
DE60030861D1 (de) 2006-11-02
US20020086899A1 (en) 2002-07-04
MY143278A (en) 2011-04-15
NO329021B1 (no) 2010-07-26
SK82002A3 (en) 2002-07-02
HK1048069B (zh) 2005-12-16
IS6137A (is) 2001-10-30
HRP20010820A2 (en) 2003-08-31
US7265151B2 (en) 2007-09-04
EP1440691A3 (en) 2004-08-25
AU2005202685B2 (en) 2009-01-15
AU782514B2 (en) 2005-08-04
ME00032B (me) 2010-02-10
IL170193A (en) 2010-04-29
ZA200108856B (en) 2002-12-24
DK1200081T3 (da) 2006-12-27
ATE339955T1 (de) 2006-10-15
EP1440690A2 (en) 2004-07-28
CA2373757C (en) 2010-01-05
IL170194A (en) 2010-05-31
EP1440691A2 (en) 2004-07-28
BG110467A (en) 2010-01-29
US20070276035A1 (en) 2007-11-29
JP2003504332A (ja) 2003-02-04
TR200402275T2 (tr) 2005-03-21
BR0011578A (pt) 2002-03-26
EA200200137A1 (ru) 2002-06-27
TR200402277T2 (tr) 2005-01-24
NO20100334L (no) 2002-01-07
AU2005202686B2 (en) 2009-01-15
US7271194B2 (en) 2007-09-18
US20050101665A1 (en) 2005-05-12
KR100604176B1 (ko) 2006-07-25
CL2008003939A1 (es) 2009-06-05
US20040029956A1 (en) 2004-02-12
HUP0201791A2 (en) 2002-10-28
AU2005202685A1 (en) 2005-07-14
HUP0201791A3 (en) 2005-02-28
EP1200081B1 (en) 2006-09-20
AU2005202684B2 (en) 2009-01-15
CO5190674A1 (es) 2002-08-29
CZ200270A3 (cs) 2002-04-17
US20040029957A1 (en) 2004-02-12
KR20020015346A (ko) 2002-02-27
ES2272298T3 (es) 2007-05-01
YU78701A (sh) 2004-03-12
NO20100335L (no) 2002-01-07
CA2687392A1 (en) 2001-01-18
EP1440689A2 (en) 2004-07-28
NO20100333L (no) 2002-01-07
US6960613B2 (en) 2005-11-01
IL146131A0 (en) 2002-07-25
CA2373757A1 (en) 2001-01-18
AU2005202684A1 (en) 2005-07-14
BG106279A (bg) 2002-08-30
CL2008003938A1 (es) 2009-05-22
AU2008264188A1 (en) 2009-05-07
PT1200081E (pt) 2007-01-31
WO2001003694A1 (en) 2001-01-18
HK1048069A1 (en) 2003-03-21
UA77645C2 (en) 2007-01-15
CA2687396A1 (en) 2001-01-18
MXPA01011626A (es) 2002-06-04
US20040029958A1 (en) 2004-02-12
PL352030A1 (en) 2003-07-28
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
EP1440689A3 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
CN1198610C (zh) 神经紊乱的治疗
EA008373B1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
Lightowler et al. At pharmacologically active doses chronic moclobemide lacks anxiolytic-like activity in the rat social interaction model
EA008372B1 (ru) Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050427